未知生产厂商
Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
Itolizumab binds to CD6 which modulates T-lymphocyte activation and proliferation. It is an efficacious immunomodulatory compound investigated for treating psoriasis. Currently, the full mechanisms of action are still unclear.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
